After the very negative Food and Drug Administration document released ahead of Johnson & Johnson (NYS: JNJ) and Bayer's advisory panel meeting on expanding the indication for Xarelto, it sure looked like the companies were headed into the firing squad.
Instead, most of the committee came to the companies' rescue. In a 9-2 vote with one abstention, the committee recommended approving Xarelto for atrial fibrillation.
While that sounds pretty close to a ringing endorsement, the FDA pays as much -- if not more -- attention to the comments about the drug and why committee members voted the way they do as they do to the actual vote. Based on reports from the meeting, it sure doesn't appear that this is a strong endorsement of Xarelto.
If anything, the vote is a vote against warfarin, the current standard of treatment. The drug is notoriously difficult to obtain the correct dose for patients. Too little and it doesn't help, and too much and there's a risk of internally bleeding. The drug is used as rat poison and kills them through that exact mechanism. Even if Xarelto isn't as effective as warfarin, the contrast in safety profiles might justify it being used in some circumstances.
Keep in mind that the FDA has the final say, though, so the reviewers' opinions in the briefing documents should be taken as the starting point. Were the vote and comments enough to sway the agency's opinion? We'll know on or around Nov. 5 when the FDA is scheduled to make a decision. My guess is that Xarelto will still get a complete response letter -- the FDA's euphemism for rejection -- but that's just a guess based on previous experience with negative briefing documents and positive panels: Dendreon (NAS: DNDN) and InterMune (NAS: ITMN) , for example.
Even if the FDA approves Xarelto for atrial fibrillation without a requirement to run any additional trials, I wouldn't count on Xarelto grabbing too much of the atrial fibrillation market. Boehringer Ingelheim's Pradaxa was recently approved to treat atrial fibrillation, and Pfizer (NYS: PFE) and Bristol-Myers Squibb's (NYS: BMY) Eliquis, will likely be approved next year, considering the outstanding data it's posted to date. The atrial fibrillation market is a decent size, but if Xarelto is relegated to a third-line therapy, the fraction of the pie isn't going to be very large.
You can follow the developments of the atrial fibrillation market by joining the Fool's free watchlist service. Just click on the links below.
AddPfizerto My Watchlist.
AddJohnson & Johnsonto My Watchlist.
AddBristol-Myers Squibbto My Watchlist.
At the time thisarticle was published
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.